Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study.

Saved in:
Bibliographic Details
Title: Elexacaftor/tezacaftor/ivacaftor in children aged ≥6 years with cystic fibrosis heterozygous for F508del and a minimal function mutation: results from a 96-week open-label extension study.
Authors: Mall MA; Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany.; German Center for Child and Adolescent Health (DZKJ), partner site, Berlin, Germany.; German Center for Lung Research (DZL), associated partner site Berlin, Berlin, Germany.; Co-lead authors., Wainwright CE; Queensland Children's Hospital, University of Queensland, South Brisbane, Australia.; Co-lead authors., Legg J; National Institute for Health Research, Southampton Respiratory Biomedical Research Centre, University Hospitals Southampton NHS Foundation Trust, Southampton, UK.; Southampton Children's Hospital, University Hospitals Southampton NHS Foundation Trust, Southampton, UK., Chilvers M; British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada., Gartner S; Hospital Universitari Vall d'Hebron, Barcelona, Spain., Dittrich AM; Department for Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Hannover, Germany.; BREATH, German Center for Lung Research (DZL), Hannover, Germany., Stehling F; Children's Hospital, University of Duisburg-Essen, Essen, Germany., Conner S; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Grant S; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Suresh N; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Weinstock TG; Vertex Pharmaceuticals Incorporated, Boston, MA, USA., Davies JC; National Heart and Lung Institute, Imperial College London, London, UK j.c.davies@imperial.ac.uk.; Royal Brompton and Harefield Hospitals, Guy's and St Thomas' NHS Trust, London, UK.; European CF Society Lung Clearance Index Core Facility, London, UK.
Corporate Authors: VX20-445-119 Study Group
Source: The European respiratory journal [Eur Respir J] 2025 Jul 14; Vol. 66 (1). Date of Electronic Publication: 2025 Jul 14 (Print Publication: 2025).
Publication Type: Journal Article; Clinical Trial, Phase III; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: European Respiratory Society Country of Publication: England NLM ID: 8803460 Publication Model: Electronic-Print Cited Medium: Internet ISSN: 1399-3003 (Electronic) Linking ISSN: 09031936 NLM ISO Abbreviation: Eur Respir J Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1399-3003
DOI:10.1183/13993003.02435-2024